Summarized by Masters of Longevity from Longevity Technology.
Interim Phase 1 data showed a 1.47 mg/dL placebo-adjusted uric acid fall.
Key Takeaways
- DA-1726 lowered serum uric acid by 1.47 mg/dL versus placebo.
- The result was from a 16-week randomized, placebo-controlled Phase 1 study.
- The finding was observed in otherwise healthy adults with obesity.
